Polygenic Risk Scores in Neurodegenerative Diseases: a Review

Purpose of the ReviewThis review summarizes the current state of the art of polygenic risk scores (PRSs) in the assessment of risk for neurodegenerative diseases.Recent FindingsPolygenic risk scores have been used to identify the shared genetic architecture between comorbid complex traits, disease presentations, and disease endophenotypes.SummaryThe pathological and symptomatologic overlap between neurodegenerative diseases is strikingly high. In some cases, the diagnostic decision is arbitrary depending on the first appearance of symptomatology. Genetic studies have demonstrated that the genetic architecture of each of these diseases is different, but has a high degree of overlap. The creation of polygenic risk scores has allowed a more accurate calculation of this overlap. However, the power of the PRS is dependent on the power of the genome-wide association studies (GWAS) used to describe the genetic architecture. Even though not all neurodegenerative disease GWAS have the same sample size, and thus the same power, the use of polygenic risk scores has been successful in demonstrating the genetic overlap that has been observed phenotypically.

[1]  R. Petersen,et al.  APOE ε4 is associated with severity of Lewy body pathology independent of Alzheimer pathology , 2018, Neurology.

[2]  P. Visscher,et al.  Common Disease Is More Complex Than Implied by the Core Gene Omnigenic Model , 2018, Cell.

[3]  C. Wallace,et al.  Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary Statistics , 2013, PLoS genetics.

[4]  A. Fagan,et al.  Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms , 2018, Alzheimer's & Dementia.

[5]  Bruce L. Miller,et al.  Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS , 2011, Neuron.

[6]  B. Ghetti,et al.  A novel mutation (G217D) in the Presenilin 1 gene (PSEN1) in a Japanese family: presenile dementia and parkinsonism are associated with cotton wool plaques in the cortex and striatum , 2002, Acta Neuropathologica.

[7]  S. Gomperts.  Lewy Body Dementias: Dementia With Lewy Bodies and Parkinson Disease Dementia , 2016, Continuum.

[8]  M. Carta,et al.  Epidemiology of early-onset dementia: a review of the literature , 2013, Clinical practice and epidemiology in mental health : CP & EMH.

[9]  Sterling C. Johnson,et al.  Pathway-Specific Polygenic Risk Scores as Predictors of Amyloid-β Deposition and Cognitive Function in a Sample at Increased Risk for Alzheimer's Disease. , 2016, Journal of Alzheimer's disease : JAD.

[10]  Andrew Lees,et al.  Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.

[11]  Rui Liu,et al.  Apolipoprotein E genotypes and the risk of Parkinson disease , 2011, Neurobiology of Aging.

[12]  Nick C Fox,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, and shows evidence for additional susceptibility genes , 2009, Nature Genetics.

[13]  O. Andreassen,et al.  Genetic architecture of sporadic frontotemporal dementia and overlap with Alzheimer's and Parkinson's diseases , 2016, Journal of Neurology, Neurosurgery & Psychiatry.

[14]  C. van Broeckhoven,et al.  The genetics of dementia with Lewy bodies: what are we missing? , 2012, Archives of neurology.

[15]  C. Jack,et al.  Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease , 2009, Brain : a journal of neurology.

[16]  A. Agrawal,et al.  Polygenic Risk Scores in Clinical Psychology: Bridging Genomic Risk to Individual Differences. , 2018, Annual review of clinical psychology.

[17]  I. Deary,et al.  Molecular Genetic Evidence for Genetic Overlap between General Cognitive Ability and Risk for Schizophrenia: A Report from the Cognitive Genomics Consortium (COGENT) , 2013, Molecular Psychiatry.

[18]  Hongyu Zhao,et al.  A powerful approach to estimating annotation-stratified genetic covariance using GWAS summary statistics , 2017, bioRxiv.

[19]  Alexander Gerhard,et al.  Frontotemporal dementia and its subtypes: a genome-wide association study , 2014, The Lancet Neurology.

[20]  I. Deary,et al.  Genetic risk for neurodegenerative disorders, and its overlap with cognitive ability and physical function , 2017, bioRxiv.

[21]  Nick C Fox,et al.  Letter abstract - Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's Disease , 2009 .

[22]  Annelot M. Dekker,et al.  Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis , 2017 .

[23]  G. Landreth,et al.  TREM2 in Neurodegenerative Diseases , 2017, Molecular Neurodegeneration.

[24]  D. Schaid,et al.  Polygenic risk scores in familial Alzheimer disease , 2017, Neurology.

[25]  M. Gill,et al.  Common polygenic variation enhances risk prediction for Alzheimer's disease. , 2015, Brain : a journal of neurology.

[26]  Jack Euesden,et al.  PRSice: Polygenic Risk Score software , 2014, Bioinform..

[27]  B. Ritz,et al.  Association of Polygenic Risk Score With Cognitive Decline and Motor Progression in Parkinson Disease , 2018, JAMA neurology.

[28]  A Smith,et al.  Genetic overlap between Alzheimer’s disease and Parkinson’s disease at the MAPT locus , 2015, Molecular Psychiatry.

[29]  P. Visscher,et al.  Common polygenic variation contributes to risk of schizophrenia and bipolar disorder , 2009, Nature.

[30]  H. Zoghbi,et al.  Neurodegeneration: From cellular concepts to clinical applications , 2016, Science Translational Medicine.

[31]  I J Deary,et al.  Major depressive disorder and current psychological distress moderate the effect of polygenic risk for obesity on body mass index , 2015, Translational Psychiatry.

[32]  Gilles Blanchard,et al.  Combining Multiple Hypothesis Testing with Machine Learning Increases the Statistical Power of Genome-wide Association Studies , 2016, Scientific Reports.

[33]  Yusuke Nakamura,et al.  Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease , 2009, Nature Genetics.

[34]  Andrey Ziyatdinov,et al.  Efficient analysis of large-scale genome-wide data with two R packages: bigstatsr and bigsnpr , 2018, Bioinform..

[35]  Polygenic analysis of inflammatory disease variants and effects on microglia in the aging brain , 2018, Molecular Neurodegeneration.

[36]  Lilah M. Besser,et al.  Polygenic hazard scores in preclinical Alzheimer’s disease , 2017, bioRxiv.

[37]  Naomi R. Wray,et al.  Estimation and partitioning of polygenic variation captured by common SNPs for Alzheimer's disease, multiple sclerosis and endometriosis , 2012, Human molecular genetics.

[38]  Chuong B. Do,et al.  Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease , 2014, Nature Genetics.

[39]  G. Schellenberg,et al.  Apolipoprotein E in Alzheimer's disease risk and case detection: a case-control study. , 1996, Journal of clinical epidemiology.

[40]  L. Liang,et al.  A genome-wide cross trait analysis from UK Biobank highlights the shared genetic architecture of asthma and allergic diseases , 2018, Nature Genetics.

[41]  M. Nalls,et al.  A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci , 2017, Nature Genetics.

[42]  Janel O. Johnson,et al.  Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study , 2012, The Lancet Neurology.

[43]  Nick C Fox,et al.  Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease , 2013, Nature Genetics.

[44]  J. Trojanowski,et al.  Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies , 2013, Nature Reviews Neuroscience.

[45]  B. Dubois,et al.  Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. , 1999, American journal of human genetics.

[46]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[47]  A. Hofman,et al.  Genetic risk of neurodegenerative diseases is associated with mild cognitive impairment and conversion to dementia , 2015, Alzheimer's & Dementia.

[48]  A. Myers,et al.  Polygenic risk score analysis of pathologically confirmed Alzheimer disease , 2017, Annals of neurology.

[49]  Pak Chung Sham,et al.  Polygenic scores via penalized regression on summary statistics , 2016, bioRxiv.

[50]  Rosa Rademakers,et al.  How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: can we learn from other noncoding repeat expansion disorders? , 2012, Current opinion in neurology.

[51]  Sonja W. Scholz,et al.  Heritability and genetic variance of dementia with Lewy bodies , 2018, Neurobiology of Disease.

[52]  J. Morris,et al.  Assessment of the Genetic Architecture of Alzheimer's Disease Risk in Rate of Memory Decline. , 2018, Journal of Alzheimer's disease : JAD.

[53]  P. Visscher,et al.  Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores , 2015, bioRxiv.

[54]  M. Glymour,et al.  Using an Alzheimer Disease Polygenic Risk Score to Predict Memory Decline in Black and White Americans Over 14 Years of Follow-up , 2016, Alzheimer disease and associated disorders.

[55]  M. Nalls,et al.  A large study reveals no association between APOE and Parkinson's disease , 2012, Neurobiology of Disease.

[56]  Carlos Cruchaga,et al.  TREM2 and neurodegenerative disease. , 2013, The New England journal of medicine.

[57]  Marc Cruts,et al.  Locus-Specific Mutation Databases for Neurodegenerative Brain Diseases , 2012, Human mutation.

[58]  D. Hernandez,et al.  Polygenic risk score in postmortem diagnosed sporadic early-onset Alzheimer's disease , 2018, Neurobiology of Aging.

[59]  Sonja W. Scholz,et al.  Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study , 2018, The Lancet Neurology.

[60]  O. Andreassen,et al.  Combining Polygenic Hazard Score With Volumetric MRI and Cognitive Measures Improves Prediction of Progression From Mild Cognitive Impairment to Alzheimer's Disease , 2018, Front. Neurosci..

[61]  Paul Fergus,et al.  Utilizing Deep Learning and Genome Wide Association Studies for Epistatic-Driven Preterm Birth Classification in African-American Women , 2018, IEEE/ACM Transactions on Computational Biology and Bioinformatics.

[62]  J. Del-Aguila,et al.  Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels , 2017, BMC Neurology.

[63]  P. Visscher,et al.  Multi-trait analysis of genome-wide association summary statistics using MTAG , 2017, Nature Genetics.

[64]  M. Barquero,et al.  New V272A presenilin 1 mutation with very early onset subcortical dementia and parkinsonism , 2004, European journal of neurology.

[65]  M. Nalls,et al.  Polygenic risk of Parkinson disease is correlated with disease age at onset , 2015, Annals of neurology.

[66]  Paul Fergus,et al.  Utilising Deep Learning and Genome Wide Association Studies for Epistatic-Driven Preterm Birth Classification in African-American Women , 2018 .

[67]  J. Haines,et al.  Apolipoprotein E is associated with age at onset of amyotrophic lateral sclerosis , 2004, Neurogenetics.

[68]  P. Deyn,et al.  DLB and PDD: a role for mutations in dementia and Parkinson disease genes? , 2012, Neurobiology of Aging.

[69]  O. Andreassen,et al.  Polygenic hazard score: an enrichment marker for Alzheimer’s associated amyloid and tau deposition , 2017, bioRxiv.

[70]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[71]  R. Sims,et al.  The Correlation between Inflammatory Biomarkers and Polygenic Risk Score in Alzheimer's Disease. , 2017, Journal of Alzheimer's disease : JAD.

[72]  A. Hofman,et al.  Variant of TREM2 associated with the risk of Alzheimer's disease. , 2013, The New England journal of medicine.

[73]  Louis Lello,et al.  Accurate Genomic Prediction of Human Height , 2017, Genetics.

[74]  Yang I Li,et al.  An Expanded View of Complex Traits: From Polygenic to Omnigenic , 2017, Cell.

[75]  L. Tan,et al.  Genetics of Frontotemporal Lobar Degeneration: From the Bench to the Clinic. , 2016, Journal of Alzheimer's disease : JAD.

[76]  A. Singleton,et al.  TREM2 variants in Alzheimer's disease. , 2013, The New England journal of medicine.

[77]  Jong Hun Kim,et al.  Analysis of neurodegenerative Mendelian genes in clinically diagnosed Alzheimer Disease , 2017, PLoS genetics.

[78]  E. Huey,et al.  FTD and ALS: a tale of two diseases. , 2011, Current Alzheimer research.

[79]  N. Cairns,et al.  Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia. , 2012, Archives of neurology.

[80]  A. Al-Chalabi,et al.  The epidemiology of ALS: a conspiracy of genes, environment and time , 2013, Nature Reviews Neurology.

[81]  J. Hardy,et al.  Polygenic score prediction captures nearly all common genetic risk for Alzheimer's disease , 2017, Neurobiology of Aging.

[82]  C. Jack,et al.  Rates of hippocampal atrophy correlate with change in clinical status in aging and AD , 2000, Neurology.